Signadori Bio
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage
€11.1MSeed+
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage
Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...